retatrutide nejm 2023 obesity trial ly3437943 Early data for demonstrates exceptional weight loss results, reaching approximately 21% placebo-adjusted weight loss by week 48. This performance significantly exceeds all other leading medications currently under Phase 2 Trial of Retatrutide
Description
21,23 Managing other preexisting GI conditions, such as gastroesophageal reflux disease or constipation, before initiating GLP-1 RAs can reduce the likelihood of severe GI AEs and improve overall tolerability
Retatrutide, like all GLP-1 receptor agonists, carries a warning about medullary thyroid carcinoma (MTC)
In contrast, services like LillyDirect streamline prescription fulfillment directly through an online platform linked with delivery services such as Amazon Pharmacy
Right now I sit at 205 pounds, which puts me 79 pounds lighter than where I started
Ann Med Surg
